HLX13 + nivolumab

HLX13 + nivolumab is a **combination therapy** composed of HLX13, a biosimilar of the anti-CTLA-4 monoclonal antibody ipilimumab, and nivolumab, an anti-PD-1 monoclonal antibody. The combination is being investigated as a first-line treatment for patients with unresectable hepatocellular carcinoma, among other solid tumors. HLX13 functions by blocking CTLA-4, thereby enhancing T cell activation and boosting the anti-tumor immune response. Nivolumab blocks PD-1, also leading to increased T cell activity. Combined, these immune checkpoint inhibitors are expected to exert a **synergistic immunotherapeutic effect** by targeting two non-redundant immune pathways, potentially improving anti-tumor efficacy over either agent alone[3][2][1].

Brand names

Yervoy (for reference ipilimumab, of which HLX13 is a biosimilar)Opdivo (for nivolumab)

Other names

HLX13 + nivolumab